Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Form 144 filed for Insmed, Inc. (INSM) reports a proposed sale of 10,000 shares of common stock through Merrill Lynch in Orlando, to be executed on or about 08/12/2025 on NASDAQ with an aggregate market value of $1,215,350. The filing lists total shares outstanding of 211,374,786, which makes the proposed block a very small fraction of the company's capitalization.
The securities to be sold were acquired via stock option transactions reported on 05/18/2018 (6,702 shares) and 05/16/2019 (6,066 shares). Several identifying fields in the filing appear blank or unspecified, and the form includes the standard representation that the seller does not possess undisclosed material adverse information.
Insmed announced FDA approval of BRINSUPRI (brensocatib) 10 mg and 25 mg tablets, an oral once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. The company attached a press release and an approval presentation as Exhibits 99.1 and 99.2 and will host a conference call with a live webcast to discuss the approval. The filing notes the Item 7.01 materials are not deemed "filed" for purposes of Section 18. The report does not include financial results, revenue guidance, launch timing, or other commercial details.
Insmed (INSM) Q2 2025 10-Q highlights
- Net sales up 19% to $107.4 m; six-month sales rose 21% to $200.2 m, driven by ARIKAYCE growth in Japan (+45%) and continued U.S. demand.
- Spending accelerated. R&D jumped 21% YoY to $177.2 m and SG&A 45% to $154.8 m. Total operating expenses were $420.3 m, lifting the operating loss to $312.9 m (-8% YoY).
- Wider bottom-line loss. Net loss reached $321.7 m (-$1.70/sh) versus $300.6 m (-$1.94/sh) a year ago; six-month loss deepened to $578.3 m.
- Balance-sheet reset. All $575 m 0.75% 2028 converts were converted/redemed in Q2, cutting long-term debt nearly 51% to $538.5 m (term loans only) and adding 17.9 m shares. Shareholders’ equity rose to $1.25 b from $0.29 b.
- Liquidity bolstered. Cash & cash equivalents soared to $1.28 b (vs. $0.56 b YE-24) after $823.5 m equity raise and $146 m draw of Tranche B term loan; total liquidity (cash+securities) $1.86 b.
- Cash burn rising. Operating cash outflow was -$468 m for H1 vs. -$307 m prior-year.
- Contingent consideration liability climbed to $246 m (+46% YTD) on Motus/AlgaeneX milestones.
Company says cash on hand funds operations for ≥12 months while it advances brensocatib Phase 3, TPIP, INS1201 and expands ARIKAYCE indications. No forward guidance provided.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
